Teriflunomide effect on immune response to influenza vaccine in patients with multiple sclerosis

Neurology

Volumn 81, Issue 6, 2013, Pages 552-558

  Bar Or, Amit ^a   Freedman, Mark S ^b   Kremenchutzky, Marcelo ^c   Menguy Vacheron, Françoise ^d   Bauer, Deborah ^d   Jodl, Stefan ^e   Truffinet, Philippe ^d   Benamor, Myriam ^d   Chambers, Scott ^f   O'Connor, Paul W ^g  

^a MCGILL UNIVERSITY   (Canada)

^b OTTAWA HOSPITAL RESEARCH INSTITUTE   (Canada)

^c UNIVERSITY OF WESTERN ONTARIO   (Canada)

^d SANOFI   (France)

^e Sanofi ^*  (Germany)

^f Fishawack Communications Ltd   (United Kingdom)

^g UNIVERSITY OF TORONTO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

BETA1 INTERFERON; INFLUENZA VACCINE; TERIFLUNOMIDE;

ADULT; ARTICLE; DRUG EFFICACY; DRUG SAFETY; FEMALE; HUMAN; IMMUNE RESPONSE; IMMUNITY; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MULTIPLE SCLEROSIS; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; SEASONAL INFLUENZA; TREATMENT DURATION;

ADULT; ANTIBODIES, VIRAL; CROTONATES; DRUG INTERACTIONS; FEMALE; HUMANS; INFLUENZA A VIRUS, H1N1 SUBTYPE; INFLUENZA A VIRUS, H3N2 SUBTYPE; INFLUENZA VACCINES; INTERNATIONALITY; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS; TOLUIDINES; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84884580887     PISSN: 00283878     EISSN: 1526632X     Source Type: Journal    
DOI: 10.1212/WNL.0b013e31829e6fbf     Document Type: Article

References (11)

1. Gold R, Wolinsky JS. Pathophysiology of multiple sclerosis and the place of teriflunomide. Acta Neurol Scand 2011;124:75-84.
2. Wolinsky JS, Narayana AP, Nelson F, et al. Magnetic resonance imaging outcomes from a phase III trial of teriflunomide. Mult Scler Epub 2013 Feb 27.
3. O'Connor P, Wolinsky JS, Confavreux C, et al. Randomized trial of oral teriflunomide for relapsing multiple sclerosis. N Engl J Med 2011;365:1293-1303.
4. Schwid SR, Decker MD, Lopez-Bresnahan M. Immune response to influenza vaccine is maintained in patients with multiple sclerosis receiving interferon beta-1a. Neurology 2005;65:1964-1966.
5. O'Connor PW, Li D, Freedman MS, et al. A phase II study of the safety and efficacy of teriflunomide in multiple sclerosis with relapses. Neurology 2006;66:894-900.
6. Confavreux C, Li DK, Freedman MS, et al. Long-term follow-up of a phase 2 study of oral teriflunomide in relapsing multiple sclerosis: safety and efficacy results up to 8.5 years. Mult Scler 2012;18:1278-1289.
7. O'Connor P,Wolinsky JS, Confavreux C, et al. Extension of a phase III trial (TEMSO) of oral teriflunomide in multiple sclerosis with relapses: clinical andMRI data 5 years after initial randomisation. Mult Scler 2011;17(suppl 17):S414.P924.
8. Comi G, O'Connor P, Wolinsky J, et al. Extension of a phase III trial (TEMSO) of oral teriflunomide in multiple sclerosis with relapses: safety outcomes with up to 4 years of follow-up. Mult Scler 2011;17(suppl 17):S182.P439.
9. European Agency for the Evaluation of Medicinal Products. Committee for Proprietary Medicinal Products: Note for Guidance on Harmonization of Requirements for Influenza Vaccines. London: European Agency for the Evaluation of Medicinal Products 1997.
10. Confavreux C, Suissa S, Saddier P, Bourdès V, Vukusic S. Vaccinations and the risk of relapse in multiple sclerosis. N Engl J Med 2001;344:319-326.
11. De Keyser J, Zwanikken C, Boon M. Effect of influenza vaccination and influenza illness on exacerbations in multiple sclerosis. J Neurol Sci 1998;195:51-53.